References
- Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993;15:48–65
- Cunnick GH, Mokbel K. Aromatase inhibitors. Curr Med Res Opin 2001;17(3):217–22
- Siiteri PK, MacDonald PC. Role of extraglandular estrogen in human endocrinology. In: Greep RO Astwood EB, eds. Handbook of Physiology. Washington DC: American Physiological Society, 1973:615–29
- Reed MJ, Hutton JD, Baxendale PM, et al. The conversion of androstenedione to oestrone and production of oestrone in women with endometrial cancer. J Steroid Biochem 1979;11:905–11
- Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973;36:207–14
- Dunn LJ, Bradbury JT. Endocrine factors in endometrial carcinoma: a preliminary report. Am J Obstet Gynecol 1967;97:465–71
- Hemsell DL, Grodin JM, Brenner PF, et al. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974;38:476–9
- Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res 2003;9(1 Pt 2):468–72S
- Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:1142–52
- Nabhotz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758–67
- Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748
- The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359(9324):2131–9
- Mokbel K. Recent advances in breast cancer: The 25th Annual San Antonio Breast Cancer Symposium. Curr Med Res Opin 2003;19:143–6
- Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 2000;6(6):2229–35
- Dixon JM, Love CDB, Renshaw L, et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer 1999;6(2):227–30
- Boeddinghaus IM, Dowsett M, Smith IE, et al. Neoadjuvant Arimidex or tamoxifen, alone or combined, for breast cancer (IMPACT): PgR-related reductions in proliferation marker Ki67. Proc Am Soc Clin Oncol 2000;19:94a (Abstr 360)
- Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive, estrogen receptor positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19: 3808–16